Clinical Trials Logo

Clinical Trial Summary

A prospective study in Beni-Seuf University Hospital that was conducted on 123 adult patients with acute asthma exacerbations. Patients were classified into group (I): received IV magnesium sulfate, group (II): received nebulized magnesium sulfate, and group (III): control group. Blood pressure, respiratory rate, pulse, peak expiratory flow rate (PEFR) measurement using a peak flowmeter, Fischl index and need for hospitalization in patients with acute bronchial asthma were done for all patients before treatment, immediately after the treatment, "30", and "60" min after treatment.


Clinical Trial Description

Inclusion criteria : - adult patients between the ages of 18 and 50 years with acute attack of bronchial asthma - from both sexes - Normal renal function - Normal cardiovascular function Exclusion criteria: - Patients were younger than 18 years or older than 50 years. - Patients suffered from chronic obstructive pulmonary disease, renal disorder and heart failure All patients were subjected to: complete history taking, blood sampling for serum magnesium measurement (on admission before the initial treatment and after the initial treatment) the patients were randomly separated into 3 equal groups each group consists of 41 patients. The 1ST group has been managed by an initial treatment plan (consists of supplemental oxygen therapy to keep oxygen saturation higher than 90%., nebulization of 1 ml salbutamol respirator solution mixed with 9 ml normal saline solution for one session [Farcolin respirator solution: each 20 ml of Farcolin contains Salbutamol sulfate 0.121 gm. Made in Egypt, by: Pharco Pharmaceuticals -Alexandria], Intravenous administration of hydrocortisone 100 mg for a single dose [Solu-Cortef: vial contains powder of 100 mg Sodium hydrocortisone sodium succinate dissolved with 2 ml solvent of sterile bacteriostatic water for IV injection. Manufactured by: Egyptian Int. Pharmaceutical Industries co. (e.i.p.i.co.) - Egypt. Under license of: Pfizer]) plus a single dose (2000 mg) of magnesium sulfate prepared by mixing 20 ml of 10 % magnesium sulfate (2000 MG) [14] ,manufactured by Memphis Pharmaceuticals and Chemical Industries, with 30 ml of distillated water for injection to produce 50 ml of isotonic magnesium sulfate solution (324 MSOM/L) administered intravenously over 1 hour. The 2nd group has been managed by the same initial treatment plan plus a single dose (2000 mg) of magnesium sulfate prepared by mixing 20 ml of 10 % magnesium sulfate (2000 MG) [14] ,manufactured by Memphis Pharmaceuticals and Chemical Industries, with 30 ml of distillated water to produce 50 ml of isotonic magnesium sulfate solution (324 MSOM/L). nebulized using jet nebulizer over 1 hour. The 3rd group has been managed by the same treatment plan Without using magnesium sulfate. (a control group) the following were recorded for each patient at a fixed interval (before the initial treatment, immediately after the initial treatment, 30, and 60 min after the initial treatment): 1. blood pressure, respiratory rate and pulse rate 2. Peak expiratory flow measurement using peak flow meter. 3. Fischl index for relapse and need for hospitalization in patients with acute bronchial asthma. [16[ . ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05908864
Study type Observational
Source Beni-Suef University
Contact
Status Completed
Phase
Start date October 30, 2018
Completion date December 15, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT05304039 - Phenotyping and Classifying Asthma Exacerbations
Not yet recruiting NCT04410120 - Impact of Asthma Exacerbations
Not yet recruiting NCT03277170 - Pragmatic RCT of High-dose Oral Montelukast for Moderate and Severe Pediatric Acute Asthma Exacerbations Phase 2
Completed NCT03967873 - Child Asthma : What Parents Attitude During an Asthma Attack at Home Before Consulting the Pediatric Emergencies
Completed NCT05318885 - The Effect of Nebulization Positions in Asthmatic Children N/A
Recruiting NCT06137040 - Timely Administration of IV Magnesium Sulfate in Patients With a Moderate Asthma Exacerbation Early Phase 1
Recruiting NCT05446090 - Asthma: Phenotyping Exacerbations 3
Enrolling by invitation NCT06201728 - The Effect of Asthma Flare-up Clinic After Exacerbation N/A
Terminated NCT05013073 - ASTHMAXcel Emergency Department Study N/A
Recruiting NCT05603494 - The Use of Home Spirometry in the Monitoring of Patients With Acute Exacerbation of Asthma N/A
Completed NCT03099915 - Asthma Attack in the Emergency Department : Reasons Of This Attendance
Recruiting NCT04501926 - Genomics and Metagenomics of Asthma Severity
Recruiting NCT05417906 - Using the Blood Eosinophil Count to Guide Systemic Corticosteroid Treatment in Asthma Exacerbations Phase 2
Recruiting NCT04617171 - Benralizumab Initiated During Severe Asthma Attack Phase 2
Recruiting NCT05748600 - A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma Phase 3
Completed NCT03705325 - Evaluating Asthma Exacerbation-induced Changes in Lung Function With a Home-based Spirometer N/A
Completed NCT04941001 - Optimisation of ASthma In Those With Uncontrolled Symptoms (OASIS) N/A
Completed NCT03642418 - User-Friendly Spirometer and Mobile App for Self-Management and Home Monitoring of Asthma Patients
Not yet recruiting NCT06377345 - Remote Patient Monitoring Solution for Chronic Respiratory Disease Management N/A